Arsanis Inc. (ASNS) Prices 4M Share IPO at $10/Sh

Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $10.00 per share. The gross proceeds to Arsanis from the offering are expected to be $40.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Arsanis has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Arsanis at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Arsanis. Arsanis’ shares are scheduled to begin trading on The NASDAQ Global Market on November 16, 2017 under the ticker symbol “ASNS.”

The offering is expected to close on November 20, 2017, subject to customary closing conditions.

In addition, a fund affiliated with New Enterprise Associates has agreed to purchase $20.0 million of Arsanis' common stock in a separate private placement concurrent with the completion of Arsanis' initial public offering at a price per share equal to the initial public offering price. The closing of the initial public offering is not conditioned upon the closing of the concurrent private placement.

Citigroup, Cowen and Company and Piper Jaffray & Co. are acting as joint book-running managers for the public offering and as placement agents for the concurrent private placement.

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch